Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients

Inhaled corticosteroids are established as maintenance therapy for persistent asthma. A new aerosol formulation of flunisolide delivers a small particle size by using a hydrofluoroalkane (HFA) propellant with a built-in spacer. To compare efficacy and safety of two different flunisolide formulations, HFA and chlorofluorocarbon (CFC), with placebo treatment over a range of doses. The multicenter, randomized, double-blind, placebo-controlled trial consisted of a 2-week, active run-in phase with CFC flunisolide 500 μg, twice daily, followed by 12 weeks of double-blind treatment with placebo, HFA flunisolide (85, 170, or 340 μg, twice daily), or CFC flunisolide (250, 500, or 1,000 μg, twice daily). Patients (N = 669) were nonsmokers, at least 12 years of age, with mild to moderate asthma who were being treated with inhaled corticosteroids. Outcome measures were change from baseline in forced expiratory volume in 1 second (FEV 1), peak expiratory flow rate, as needed albuterol use, nocturnal awakenings, and asthma symptoms. After 12 weeks of treatment, patients receiving 170 μg, twice daily, and 340 μg, twice daily, of HFA flunisolide showed a significant ( P < 0.01) improvement in percentage increase in FEV 1 (12.22% at 170 μg, twice daily, and 14.69% at 340 μg, twice daily) compared with the placebo group (5.35%). At one-third the dose of CFC flunisolide, HFA flunisolide provided similar improvement in pulmonary function versus placebo. Both formulations demonstrated comparable linear dose dependency for the change from baseline in FEV 1 without any evidence of cortisol suppression. Outcome values for all seven secondary efficacy measures were numerically superior in patients receiving HFA flunisolide compared with the CFC formulation. Both formulations seemed to be safe and well tolerated. HFA flunisolide provides comparable efficacy and safety at one-third the dose of CFC flunisolide.